A new treatment is among the first known to reduce the severity of acute respiratory distress syndrome caused by the flu in animals, according to a new study. Tests in mice infected with high doses of ...

In a new report posted online in the American Journal of Respiratory and Critical Care Medicine, a global consensus conference of 32 critical care experts with broad international representation and ...

Unlike current treatment methods, SWAZA-1 is noninvasive, simple to administer, and low-cost. The novel technology can be easily administered via nebulization, allowing for early intervention. This ...

DUBLIN--(BUSINESS WIRE)--The "Global Acute Respiratory Distress Syndrome Market (2024 Edition): Market Size, Trends, Opportunities and Forecast by End-User, Mode of Administration, Treatment Mode, ...

Drawing from research on sepsis and complement biology, they developed the monoclonal antibody vilobelimab to block overactive inflammatory responses in patients with severe inflammatory diseases ...

The "Australia Acute Respiratory Distress Syndrome Market Analysis 2025" report has been added to ResearchAndMarkets.com's offering. The Australia Acute Respiratory Distress Syndrome (ARDS) Market is ...

Intervention/Treatment: The study tests the drug bevacizumab, administered as a single IV dose of 500 mg, against a placebo. Bevacizumab is intended to treat ARDS by potentially improving patient ...

New research suggests that alpha-1 antitrypsin could be an effective option for treating those with COVID-related acute respiratory distress syndrome (ARDS). In their study, published in the journal ...

Breathing troubles can feel frightening, especially when the cause is serious. Among the many lung conditions, two names that often come up are pneumonia and Acute Respiratory Distress Syndrome (ARDS) ...

Intervention/Treatment: The study tests vilobelimab, an experimental drug administered intravenously, against a placebo. Vilobelimab is designed to treat ARDS by potentially reducing inflammation and ...